Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.39 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL577415 | 1.00 | CHRNA7 (0.48) | CHRNA7ALDH1A1SMN1; SMN2KDM4EGAA | |
| SCHEMBL84808 | 1.00 | CHRNA7 (0.48) | CHRNA7ALDH1A1SMN1; SMN2KDM4EGAA | |
| SCHEMBL6657817 | 1.00 | CHRNA7 (0.48) | CHRNA7ALDH1A1SMN1; SMN2KDM4EGAA | |
| SCHEMBL262312 | 1.00 | — | — | |
| Ammonia Solution, Strong SCHEMBL4249875 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL14482129 | 0.96 | CHRNA7 (0.46) | CHRNA7ALDH1A1SMN1; SMN2KDM4EGAA | |
| Iodide SCHEMBL11554007 | 0.96 | CHRNA7 (0.46) | CHRNA7ALDH1A1SMN1; SMN2KDM4EGAA | |
| Methylamine SCHEMBL21065237 | 0.92 | GAA (0.46) | CHRNA7ALDH1A1SMN1; SMN2KDM4EGAA | |
| Bromide SCHEMBL6660869 | 0.92 | CHRNA7 (0.44) | CHRNA7ALDH1A1SMN1; SMN2KDM4EGAA | |
| SCHEMBL19679814 | 0.89 | KMT2A (0.46) | CHRNA7ALDH1A1SMN1; SMN2KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240297344-A1 | NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-05 | — | — | US | disclosed |
| US-20230226227-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USES THEREOF | ADVANCED ACCELERATOR APPLICATIONS ITALY SRL (IT) | 2023-07-20 | — | — | US | disclosed |
| CN-115911573-A | Nonaqueous electrolyte solution for secondary battery and nonaqueous electrolyte secondary battery using same | 三菱化学株式会社 | 2023-04-04 | — | — | CN | disclosed |
| US-11616253-B2 | Nonaqueous electrolyte for secondary battery and nonaqueous-electrolyte secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2023-03-28 | — | — | US | disclosed |
| US-20220278370-A1 | NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-09-01 | — | — | US | disclosed |
| US-11367899-B2 | Nonaqueous electrolyte for secondary battery and nonaqueous-electrolyte secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-06-21 | — | — | US | disclosed |
| EP-2691443-B1 | CONJUGATED LIPOMERS AND USES THEREOF | MASSACHUSETTS INST TECHNOLOGY (US) | 2021-02-17 | — | — | EP | disclosed |
| CN-106848406-B | Nonaqueous electrolyte solution for secondary battery and nonaqueous electrolyte secondary battery | 三菱化学株式会社 | 2020-09-11 | — | — | CN | disclosed |
| CN-111048841-A | Nonaqueous electrolyte solution for secondary battery and nonaqueous electrolyte secondary battery using same | 三菱化学株式会社 | 2020-04-21 | — | — | CN | disclosed |
| CN-105633345-B | Nonaqueous electrolyte solution for secondary battery and nonaqueous electrolyte secondary battery using same | 三菱化学株式会社 | 2020-01-17 | — | — | CN | disclosed |
| US-20100119956-A1 | NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20100055043-A1 | Poly-Halo Metal X-ray Contrast Agents | MALLINCKRODT INC. | 2010-03-04 | — | — | US | disclosed |
| EP-2144321-A1 | NONAQUEOUS ELECTROLYTE FOR RECHARGEABLE BATTERY, AND RECHARGEABLE BATTERY WITH NONAQUEOUS ELECTROLYTE | Mitsubishi Chemical Corporation (JP) | 2010-01-13 | — | — | EP | disclosed |
| US-20090053137-A1 | Chelating Conjugates Having a Substituted Aromatic Moiety and Derivatives Thereof | SpecGx LLC | 2009-02-26 | — | — | US | disclosed |
| US-7385054-B2 | Trimeric, macrocyclically substituted halo-benzene derivatives | SCHERING AG (DE) | 2008-06-10 | — | — | US | disclosed |
| US-7344704-B2 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of intravascular thrombi | SCHERING AG (DE) | 2008-03-18 | — | — | US | disclosed |
| US-20080058636-A1 | METHODS OF MYOCARDIAL IMAGING | EPIX PHARMACEUTICALS, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080044360-A1 | METHODS OF COLLAGEN IMAGING | EPIX PHARMACEUTICALS, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20070293656-A1 | COLLAGEN BINDING PEPTIDES | EPIX PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070269384-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media for diagnosis of Alzheimer's disease | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090053137-A1 | Chelating Conjugates Having a Substituted Aromatic Moiety and Derivatives Thereof | SLC30A5, SLC40A1, SLC46A1 | CHRNA7 4711/4885ALDH1A1 905/4885SMN1; SMN2 2448/4885 |
| US-20080058636-A1 | METHODS OF MYOCARDIAL IMAGING | FABP3, TNNI3, TNNT2 | CHRNA7 3169/4885ALDH1A1 4515/4885SMN1; SMN2 3414/4885 |
| US-20080044360-A1 | METHODS OF COLLAGEN IMAGING | COL14A1, COL2A1, COL1A1 | CHRNA7 3830/4885ALDH1A1 4592/4885SMN1; SMN2 2409/4885 |
| US-20070269384-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media for diagnosis of Alzheimer's disease | APP, APBA1, PSEN1 | CHRNA7 1183/4885ALDH1A1 2656/4885SMN1; SMN2 1117/4885 |
| US-20070293656-A1 | COLLAGEN BINDING PEPTIDES | COL14A1, COL2A1, COL1A1 | CHRNA7 4098/4885ALDH1A1 4339/4885SMN1; SMN2 2819/4885 |
| US-20100055043-A1 | Poly-Halo Metal X-ray Contrast Agents | SLC39A3, ZNF277, TPR | CHRNA7 4788/4885ALDH1A1 3268/4885SMN1; SMN2 4835/4885 |
| US-20230226227-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USES THEREOF | KLK3, FOLH1, BPHL | CHRNA7 4315/4885ALDH1A1 2088/4885SMN1; SMN2 4687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.